These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33111087)

  • 1. Repurposing the Native Type I-F CRISPR-Cas System in
    Xu Z; Li Y; Yan A
    STAR Protoc; 2020 Jun; 1(1):100039. PubMed ID: 33111087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native CRISPR-Cas-Mediated Genome Editing Enables Dissecting and Sensitizing Clinical Multidrug-Resistant P. aeruginosa.
    Xu Z; Li M; Li Y; Cao H; Miao L; Xu Z; Higuchi Y; Yamasaki S; Nishino K; Woo PCY; Xiang H; Yan A
    Cell Rep; 2019 Nov; 29(6):1707-1717.e3. PubMed ID: 31693906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
    Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
    Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-based Genome Editing of Pseudomonas aeruginosa.
    Chen W; Ji Q
    Methods Mol Biol; 2024; 2721():3-12. PubMed ID: 37819511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting endogenous CRISPR-Cas system for multiplex genome editing in Clostridium tyrobutyricum and engineer the strain for high-level butanol production.
    Zhang J; Zong W; Hong W; Zhang ZT; Wang Y
    Metab Eng; 2018 May; 47():49-59. PubMed ID: 29530750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the native type I-B CRISPR-Cas for genome editing in a polyploid archaeon.
    Cheng F; Gong L; Zhao D; Yang H; Zhou J; Li M; Xiang H
    J Genet Genomics; 2017 Nov; 44(11):541-548. PubMed ID: 29169919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the type I CRISPR-Cas systems for genome editing in prokaryotes.
    Xu Z; Li Y; Li M; Xiang H; Yan A
    Environ Microbiol; 2021 Feb; 23(2):542-558. PubMed ID: 32510745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of direct repeats and spacers of CRISPR/Cas systems type I-F in Brazilian clinical strains of Pseudomonas aeruginosa.
    Luz ACO; da Silva JMA; Rezende AM; de Barros MPS; Leal-Balbino TC
    Mol Genet Genomics; 2019 Oct; 294(5):1095-1105. PubMed ID: 31098740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9-Based Genome Editing and Cytidine Base Editing in
    Wang Y; Wang Z; Ji Q
    STAR Protoc; 2020 Jun; 1(1):100025. PubMed ID: 33111078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa.
    van Belkum A; Soriaga LB; LaFave MC; Akella S; Veyrieras JB; Barbu EM; Shortridge D; Blanc B; Hannum G; Zambardi G; Miller K; Enright MC; Mugnier N; Brami D; Schicklin S; Felderman M; Schwartz AS; Richardson TH; Peterson TC; Hubby B; Cady KC
    mBio; 2015 Nov; 6(6):e01796-15. PubMed ID: 26604259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient genome editing for Pseudomonas aeruginosa using CRISPR-Cas12a.
    Lin Z; Li H; He L; Jing Y; Pistolozzi M; Wang T; Ye Y
    Gene; 2021 Jul; 790():145693. PubMed ID: 33961975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transferrable and integrative type I-F Cascade for heterologous genome editing and transcription modulation.
    Xu Z; Li Y; Cao H; Si M; Zhang G; Woo PCY; Yan A
    Nucleic Acids Res; 2021 Sep; 49(16):e94. PubMed ID: 34157103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characteristics and phylogenetic analysis of Brazilian clinical strains of Pseudomonas aeruginosa harboring CRISPR/Cas systems.
    de Oliveira Luz AC; da Silva Junior WJ; do Nascimento Junior JB; da Silva JMA; de Queiroz Balbino V; Leal-Balbino TC
    Curr Genet; 2021 Aug; 67(4):663-672. PubMed ID: 33751147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient dual-negative selection for bacterial genome editing.
    Cianfanelli FR; Cunrath O; Bumann D
    BMC Microbiol; 2020 May; 20(1):129. PubMed ID: 32448155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized protocol to create deletion in adherent cell lines using CRISPR/Cas9 system.
    Farooq U; Notani D
    STAR Protoc; 2021 Dec; 2(4):100857. PubMed ID: 34746853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An efficient and versatile CRISPR-Cas9 system for genetic manipulation of multi-drug resistant
    McConville TH; Giddins MJ; Uhlemann AC
    STAR Protoc; 2021 Mar; 2(1):100373. PubMed ID: 33733242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for precision editing of endogenous Chlamydomonas reinhardtii genes with CRISPR-Cas.
    Nievergelt AP; Diener DR; Bogdanova A; Brown T; Pigino G
    STAR Protoc; 2024 Mar; 5(1):102774. PubMed ID: 38096061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-Mediated Genome Editing for
    Zhang N; He J; Muhammad A; Shao Y
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.